Chronic Diseases Drive Growth in Global GPCR Targeting Market

As chronic diseases become more prevalent and personalized medicine gains ground, the global market for G protein-coupled receptor (GPCR) targeting technologies is projected to grow from US$4.4 billion in 2024 to US$6.1 billion by 2029, according to a new report by BCC Research. 

“GPCRs continue to be critical targets in drug development for a broad range of conditions, including cancer, neurological, and cardiovascular diseases,” says BCC Research. “Emerging technologies such as AI and cryo-electron microscopy are enabling more precise targeting, fueling market expansion.”

The report attributes market growth to three primary drivers: the rising incidence of chronic conditions, the increased demand for GPCR-targeting therapeutics, and the development of new technologies that accelerate drug discovery. Tools like cryo-EM and advanced screening methods are improving the precision of GPCR-focused research, while AI is enhancing compound discovery and optimization.

Applications for GPCR-targeted drugs span oncology, central nervous system disorders, cardiovascular diseases, and respiratory illnesses. Among the product types, cell lines are expected to represent the largest market share by 2029. The demand for functional and binding assays is also rising as drug developers seek improved accuracy in screening and evaluation processes.

GPCRs play a role in essential biological functions including vision, taste, and immune system signaling. With more than 800 GPCRs identified in humans, their relevance extends across a wide range of physiological and pathological processes.

Asia-Pacific is expected to be the fastest-growing regional market, driven by increased pharmaceutical R&D activity, rising healthcare needs, and supportive public policies. North America and the European Union continue to dominate in overall market size, supported by established life sciences infrastructure and the presence of leading biotech firms.

Key market participants include Promega, Thermo Fisher Scientific, Merck KGaA, Agilent Technologies, Danaher, and Eurofins Scientific, reads the report. It also profiles startups driving innovation, such as Confo Therapeutics, which focuses on conformational GPCR modulation, Tectonic Therapeutic’s work in immune-related drug discovery, and Syn Vivo’s advanced microfluidic platforms for real-time cell assays.